Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
DoD, Breast Cancer, Transformative Breast Cancer Consortium Award
The Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
Applicants must bring together different
perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer.
The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system.
The consortium should have at least four, but no more than five, teams investigating different projects under a central hypothesis.
No more than two teams may be based at one institution.
Each team’s work must be integrated within the consortium so that every component is working toward the consortium’s central hypothesis.
Note:
This award is not intended to replace, supplement, duplicate, or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPOREs), and it should not represent a collection of related Program Project grants or subprojects.
The proposed consortium’s work is expected to be innovative; the Transformative Breast Cancer Consortium Award will include funds for “seed projects” to pursue brand new, high-risk/high-reward concepts during the award period.
Preference will be given to applications that include one or more of the following:
Different disciplines that come together with one overarching plan to address ending breast cancer with an ecologic approach.
An ecologic approach is one that brings together the different perspectives that affect the complexity of breast cancer and their interdependence, or looks at all aspects of the disease and brings together these different perspectives.
Research that includes truly innovative and brand new paradigms in breast cancer that will address vital issues in a unique way.
The issues may be one of the FY20 BCRP Overarching Challenges, the intersection of multiple Overarching Challenges, or with justification, may be a different issue that meets the intent of the award mechanism and addresses the mission of ending breast cancer.
A plan for a deep, definitive dive into one of the FY20 BCRP Overarching Challenges or a fundamental issue that has not yet been asked or answered in a manner that has not yet been attempted.
Although not all inclusive, applications that propose the following as the primary effort(s) or central hypothesis of the consortium will not meet the intent of this award mechanism:
NCI Program Project or SPORE grants or applications Conducting drug screens or testing a “cocktail” of therapeutics Targeting a single gene or protein Developing a new derivative or formulation of an old drug Conducting genomic landscape mapping analyses Seeking to improve existing technologies (e.g., mammography or magnetic resonance imaging [MRI] screening) Synergistic, highly integrated, multidisciplinary, and multi-institutional research teams of leading scientists, clinicians, and consumer advocates must be assembled into a consortium to address a major problem in a way that could not be accomplished by a single investigator or group.
While the teams are made up of different groups, each with its own Principal Investigator (PI), the teams must be working on the major problem identified in the Transformative Breast Cancer Consortium Award application and under the leadership of the Consortium Director.
The research proposed in Transformative Breast Cancer Consortium Award applications may include Phase I clinical trials and collaborations with pharmaceutical or biotechnology industry scientists and/or companies, as appropriate.
However, a clinical trial is not required, and the primary thrust of application should not be a clinical trial.
Applicants must bring together different
perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer.
The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system.
The consortium should have at least four, but no more than five, teams investigating different projects under a central hypothesis.
No more than two teams may be based at one institution.
Each team’s work must be integrated within the consortium so that every component is working toward the consortium’s central hypothesis.
Note:
This award is not intended to replace, supplement, duplicate, or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPOREs), and it should not represent a collection of related Program Project grants or subprojects.
The proposed consortium’s work is expected to be innovative; the Transformative Breast Cancer Consortium Award will include funds for “seed projects” to pursue brand new, high-risk/high-reward concepts during the award period.
Preference will be given to applications that include one or more of the following:
Different disciplines that come together with one overarching plan to address ending breast cancer with an ecologic approach.
An ecologic approach is one that brings together the different perspectives that affect the complexity of breast cancer and their interdependence, or looks at all aspects of the disease and brings together these different perspectives.
Research that includes truly innovative and brand new paradigms in breast cancer that will address vital issues in a unique way.
The issues may be one of the FY20 BCRP Overarching Challenges, the intersection of multiple Overarching Challenges, or with justification, may be a different issue that meets the intent of the award mechanism and addresses the mission of ending breast cancer.
A plan for a deep, definitive dive into one of the FY20 BCRP Overarching Challenges or a fundamental issue that has not yet been asked or answered in a manner that has not yet been attempted.
Although not all inclusive, applications that propose the following as the primary effort(s) or central hypothesis of the consortium will not meet the intent of this award mechanism:
NCI Program Project or SPORE grants or applications Conducting drug screens or testing a “cocktail” of therapeutics Targeting a single gene or protein Developing a new derivative or formulation of an old drug Conducting genomic landscape mapping analyses Seeking to improve existing technologies (e.g., mammography or magnetic resonance imaging [MRI] screening) Synergistic, highly integrated, multidisciplinary, and multi-institutional research teams of leading scientists, clinicians, and consumer advocates must be assembled into a consortium to address a major problem in a way that could not be accomplished by a single investigator or group.
While the teams are made up of different groups, each with its own Principal Investigator (PI), the teams must be working on the major problem identified in the Transformative Breast Cancer Consortium Award application and under the leadership of the Consortium Director.
The research proposed in Transformative Breast Cancer Consortium Award applications may include Phase I clinical trials and collaborations with pharmaceutical or biotechnology industry scientists and/or companies, as appropriate.
However, a clinical trial is not required, and the primary thrust of application should not be a clinical trial.
Agency: Department of Defense
Office: Dept. of the Army -- USAMRAA
Estimated Funding: $32,000,000
Office: Dept. of the Army -- USAMRAA
Estimated Funding: $32,000,000
Obtain Full Opportunity Text:
Link to Opportunity in SAMS Domestic
Additional Information of Eligibility:
Eligibility is open to international and Pakistan-based non-profit organizations.
Organizations may sub-award or sub-contract with other entities, but only one non-profit organization can be the prime recipient of the award.
Pakistan government entities are not eligible to apply.
For-profit entities are not eligible to be the prime recipient of an award under this NOFO.
When sub-awarding or sub-contracting with other entities, the responsibilities of each entity must be clearly defined in the proposal.
The applicants must submit proof of their non-profit status with their proposal submission (e.g.
proof of 501(c) (3) status, Pakistan NGO license).
Applications that do not include proof of non-profit status will not be considered for an award.
Individuals are not eligible for an award under this NOFO.
U.S.-based or registered organizations should provide proof of registration to operate in Pakistan or have a documented agreement with a partner organization registered to operate in Pakistan.
Please refer to Section D for funding restrictions.
Full Opportunity Web Address:
https://mygrants.servicenowservices.com/grants?id=grants_funding_opportunity&table=u_domestic_funding_opportunity&sys_id=5441f8f41be4105000f2ea4ce54bcba8&view=Default
Contact:
Agency Email Description:
CDMRP Help Desk
Agency Email:
Date Posted:
2020-04-30
Application Due Date:
Archive Date:
2020-11-05
Follow @topgovtgrant
Social Entrepreneurship
Spotlight
Social Enterprise Piles Textbooks for Change
Textbooks for Change, a London-based social enterprise that has obtained the B Corporation seal for positive social and environmental impact, is seeking investors that would be helping the company expand.
Nonprofit Jobs in Alabama
Fundraising & Development Jobs
Social Services Employment
Substance Abuse Jobs
Program Director Jobs
Social Services Jobs
Learn How to Identify and Avoid Grant Scams
